Streetbeat News

Products Services

SPOT

Spotify has announced adjustments to its Premium subscription prices in the US. The new prices are: Individual $11.99, Duo $16.99, Family $19.99, and Student $5.99. This change aims to support continued investment and innovation in Spotify's product features.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:35 pm

BPTH

GME

NTLA

Market-Moving News for June 3rd includes significant updates for GameStop (GME), Bio-Path Holdings (BPTH), and Intellia Therapeutics (NTLA). 'Roaring Kitty' revealed a massive GME position, BPTH presented interim results from a Phase 2 study, and NTLA announced long-term data from a Phase 1/2 study.

Portfolio Pulse from ryanfaloona@benzinga.com

June 03, 2024 | 12:35 pm

NXL

Nexalin Technology has received feedback from the FDA and reached a consensus on the design for its planned clinical studies of the Gen-3 HALO Clarity Headset Device, which targets anxiety and insomnia.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:34 pm

CEI

Camber Energy has received a Notice of Allowance for its patent application on wildfire mitigation technology, with the patent expected to be issued soon by the USPTO.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:33 pm

SHOT

Safety Shot has launched a new 4-ounce beverage designed to reduce blood alcohol content by supporting metabolism within 30 minutes. This product is aimed at on-the-go use and represents a significant innovation in the beverage industry.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:31 pm

TMUS

VPLM

VZ

VoIP-Pal has filed patent infringement lawsuits against Verizon and T-Mobile, alleging that both companies have infringed on its 'Routing, Billing, and Rating' patents.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:31 pm

ABBV

LULU

SYY

TJX

On CNBC's 'Halftime Report Final Trades,' analysts recommended TJX Companies, AbbVie, Sysco, and Lululemon. TJX reported strong Q1 FY25 results, AbbVie received positive CHMP opinion for SKYRIZI®, Sysco missed Q3 FY24 sales estimates, and Lululemon announced an updated operational structure.

Portfolio Pulse from Avi Kapoor

June 03, 2024 | 12:30 pm

BCTX

BriaCell presented promising clinical efficacy data for its Bria-IMT therapy in a Phase 2 study for advanced metastatic breast cancer at ASCO 2024. The therapy showed doubled Progression-Free-Survival (PFS) and Clinical Benefit Rate compared to historical results, and was well-tolerated with no related discontinuations.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:29 pm

AAPL

LOW

Lowe's has launched an Apple Vision Pro-powered in-store experience, starting with a pilot in three test markets this month. Customers can use Lowe's Style Studio and spatial computing to visualize and design their dream kitchens.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:28 pm

REPL

Replimune Group, Inc. (NASDAQ: REPL) presented promising clinical data from its RP1 and RP2 programs at the 2024 ASCO Annual Meeting. The 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma showed an overall response rate of 32.7%. Additionally, RP2 as monotherapy and in combination with nivolumab in uveal melanoma demonstrated an overall response rate of nearly 30%.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:26 pm